The functional effect of atorvastatin dose-dependent via inflammation factors on acute ST segment elevation...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute ST-segment elevation myocardial infarction (MI) is a critical cardiovascular event.
• Emergency percutaneous coronary intervention (PCI) is a standard treatment for acute MI.
• Statins, like atorvastatin, are crucial for managing cardiovascular risk post-MI.

Purpose of the Study:

• To compare the efficacy of high-dose (40 mg/day) versus moderate-dose (20 mg/day) atorvastatin.
• To evaluate the impact of different atorvastatin doses on major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation MI post-PCI.

Main Methods:

• A prospective study involving 265 patients with acute ST-segment elevation MI undergoing emergency PCI.
• Patients were randomized to receive either high-dose (133 patients) or moderate-dose (132 patients) atorvastatin for 1 year.
• Primary endpoints included cardiovascular death, spontaneous MI, and unplanned revascularization.

Main Results:

• High-dose atorvastatin resulted in lower LDL cholesterol levels compared to moderate-dose (1.6 ± 0.6 vs. 1.8 ± 0.6, P=0.041).
• MACE significantly decreased in the high-dose group (9.8% vs. 18.2%, P=0.03), driven by reductions in spontaneous MI (6.8% vs. 12.8%, P=0.03) and unplanned revascularization (5.2% vs. 8.3%, P=0.03).
• No significant difference in adverse event rates was observed between the two groups.

Conclusions:

• High-dose atorvastatin demonstrates superior long-term clinical performance compared to moderate-dose in patients with acute ST-segment elevation MI following emergency PCI.
• The findings support the use of high-dose atorvastatin for improved outcomes in this patient population.